Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Active:	No
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04855136
Trial Phases:	Phase I Phase II	Protocol IDs:	BB2121-MM-007 (primary) NCI-2021-07135 2020-003248-10
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Celgene
NCI Full Details:	http://clinicaltrials.gov/show/NCT04855136

Summary

This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to
determine the safety, tolerability, efficacy, PK of bb2121 in combination with other
therapies in adult subjects with R/RMM.

The following combinations will be

- Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone)

- Arm B will test bb2121 in combination with BMS-986405 (JSMD194)

Combination agents being tested may be administered before, concurrently with and/or
following (ie, maintenance) bb2121 infusion.

The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose
expansion may occur in one or more arms.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.